Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

NCT04282044 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Triple Negative Breast Cancer
Colorectal Cancer
Hepatocellular Carcinoma
Osteosarcoma
Epithelial Ovarian Cancer
Gastric Cancer
Non-small Cell Lung Cancer
Malignant Melanoma

Interventions

BIOLOGICAL: CRX100 suspension for infusion
COMBINATION_PRODUCT: Fludarabine
COMBINATION_PRODUCT: Cyclophosphamide

Sponsor

BioEclipse Therapeutics